Abstract:Background Current immunotherapies still have limited successful rates among cancers. It is now recognized that T cell functional state in the tumor microenvironment (TME) is a key determinant for effective antitumor immunity and immunotherapy. In addition to exhaustion, cellular senescence in tumor-infiltrating T cells (TILs) has recently been identified as an important T cell dysfunctional state induced by various malignant tumors. Therefore, a better understanding of the molecular mechanism responsible for T cell senescence in the TME and development of novel strategies to prevent effector T cell senescence are urgently needed for cancer immunotherapy. Methods Senescent T cell populations in the TMEs in mouse lung cancer, breast cancer, and melanoma tumor models were evaluated. Furthermore, T cell senescence induced by mouse tumor and regulatory T (Treg) cells in vitro was determined with multiple markers and assays, including real-time PCR, flow cytometry, and histochemistry staining. Loss-of-function strategies with pharmacological inhibitors and the knockout mouse model were used to identify the potential molecules and pathways involved in T cell senescence. In addition, melanoma mouse tumor immunotherapy models were performed to explore the synergistical efficacy of antitumor immunity via prevention of tumor-specific T cell senescence combined with anti-programmed death-ligand 1 (anti-PD-L1) checkpoint blockade therapy. Results We report that both mouse malignant tumor cells and Treg cells can induce responder T cell senescence, similar as shown in human Treg and tumor cells. Accumulated senescent T cells also exist in the TME in tumor models of lung cancer, breast cancer and melanoma. Induction of ataxia-telangiectasia mutated protein (ATM)-associated DNA damage is the cause for T cell senescence induced by both mouse tumor cells and Treg cells, which is also regulated by mitogen-activated protein kinase (MAPK) signaling. Furthermore, blockages of ATM-associated DNA damage and/or MAPK signaling pathways in T cells can prevent T cell senescence mediated by tumor cells and Treg cells in vitro and enhance antitumor immunity and immunotherapy in vivo in adoptive transfer T cell therapy melanoma models. Importantly, prevention of tumor-specific T cell senescence via ATM and/or MAPK signaling inhibition combined with anti-PD-L1 checkpoint blockade can synergistically enhance antitumor immunity and immunotherapy in vivo. Conclusions These studies prove the novel concept that targeting both effector T cell senescence and exhaustion is an effective strategy and can synergistically enhance cancer immunotherapy.

Senescence and Immunoregulation in the Tumor Microenvironment

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies

Immunosenescence: a key player in cancer development

Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment

Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment

Impact and potential value of immunosenescence on solid gastrointestinal tumors

Senescent Stromal Cells in the Tumor Microenvironment: Victims or Accomplices?

Tumor-Associated Senescent Macrophages, Their Markers, and Their Role in Tumor Microenvironment

Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?

The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Senescent T cells: a potential biomarker and target for cancer therapy

Abstract SoA2-01: Cellular senescence: The senescence-associated secretory phenotype (SASP) and immunity

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

T cell senescence: a new perspective on immunotherapy in lung cancer

Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy

Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity

The senescence journey in cancer immunoediting

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Asymmetric Somatic Stem Cells Division Plays a Critical Role in Cell Senescence